FORBIUS
Forbius (Formation Biologics) is a clinical-stage company that designs and develops biotherapeutics for the treatment of cancer and fibrotic diseases. The company is developing agents targeting the transforming growth factor-beta (TGF-beta) and epidermal growth factor receptor (EGFR) pathways, enabling doctors to have highly active inhibitors of validated pathways that have a differentiated mechanism of action. Forbius’ medicines are designed to radically transform patients’ lives. Their strength is utilizing their knowledge of biology and diverse protein engineering technologies to design superior inhibitors of validated biological pathways. Forbius was founded in 2011 as a management-led spin-out from YM BioSciences, prior to YM's acquisition by Gilead.
FORBIUS
Industry:
Biotechnology Health Care Pharmaceutical
Founded:
2011-01-01
Address:
Austin, Texas, United States
Country:
United States
Website Url:
http://www.forbius.com
Total Employee:
11+
Status:
Active
Contact:
(164) 725-5133
Email Addresses:
[email protected]
Total Funding:
21.98 M USD
Technology used in webpage:
SPF US Privacy User Signal Mechanism WordPress 6.0 Twemoji DMARC KnowBe4 DreamHost Hosting Dreamhost DNS Cisco Ironport Cloud Dmarcian
Current Advisors List
Current Employees Featured
Founder
Investors List
HBM Partners
HBM Partners investment in Series C - Forbius
Cancer Prevention and Research Institute of Texas
Cancer Prevention and Research Institute of Texas investment in Grant - Forbius
BioCanRx
BioCanRx investment in Grant - Forbius
Lumira Ventures
Lumira Ventures investment in Series B - Forbius
HBM Healthcare Investments AG
HBM Healthcare Investments AG investment in Series B - Forbius
Rosseau Asset Management
Rosseau Asset Management investment in Venture Round - Forbius
Lumira Ventures
Lumira Ventures investment in Venture Round - Forbius
MaRS Investment Accelerator Fund
MaRS Investment Accelerator Fund investment in Venture Round - Forbius
Toronto Innovation Acceleration Partners
Toronto Innovation Acceleration Partners investment in Venture Round - Forbius
Creative Destruction Lab (CDL)
Creative Destruction Lab (CDL) investment in Series A - Forbius
Official Site Inspections
http://www.forbius.com
- Host name: a16e665f42988324c.awsglobalaccelerator.com
- IP address: 76.223.105.230
- Location: Seattle United States
- Latitude: 47.54
- Longitude: -122.3032
- Metro Code: 819
- Timezone: America/Los_Angeles
- Postal: 98108
More informations about "Forbius"
Forbius - Crunchbase Company Profile & Funding
Forbius (Formation Biologics) is a clinical-stage company that designs and develops biotherapeutics for the treatment of cancer and fibrotic diseases. …See details»
Forbius - LinkedIn
Forbius | 2,360 followers on LinkedIn. A clinical stage company that designs and develops biotherapeutics for the treatment of cancer and fibrotic diseases. | About Forbius: Targeting …See details»
Forbius 2025 Company Profile: Valuation, Investors, Acquisition
When was Forbius founded? Forbius was founded in 2011. Where is Forbius headquartered? Forbius is headquartered in Montreal, Canada. What is the size of Forbius? Forbius has 37 …See details»
Forbius Company Profile - Office Locations, Competitors ... - Craft
Sep 21, 2020 Forbius (also known as Formation Biologics) is a protein engineering company that develops biotherapeutics for the treatment of cancer and fibrotic diseases. It provides …See details»
Forbius
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.See details»
Forbius - Funding, Financials, Valuation & Investors - Crunchbase
Forbius is a biopharmaceutical company that develops and designs niotherapeutics for the treatment of fibrotic diseases and cancers. New. Resources. ... How much funding has this …See details»
Forbius Headquarters and Office Locations - Craft.co
Forbius Headquarters and Office Locations. Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit. Button CTA. Forbius is headquartered in Austin, 701 Brazos St …See details»
Forbius - VentureRadar
Forbius (Formation Biologics) is a clinical-stage protein engineering company that designs and develops biotherapeutics for the treatment of cancer and fibrotic diseases. Forbius was …See details»
Forbius Inc - Company Profile and News - Bloomberg Markets
Company profile page for Forbius Inc including stock price, company news, executives, board members, and contact informationSee details»
Biobank Operations Specialist - Montreal - Forbius (Formation …
About Forbius Forbius (Formation Biologics) is a clinical-stage protein engineering company that specializes in designing, developing, and commercializing biotherapeutics for the treatment of …See details»
Bristol Myers Squibb Enters Agreement to Acquire Forbius
Aug 24, 2020 About Forbius. Forbius is a clinical-stage protein engineering company that develops biotherapeutics to treat fibrosis and cancer. Forbius’ team of TGF-beta biology …See details»
Forbius Stock Price, Funding, Valuation, Revenue & Financial …
See Forbius funding rounds, investors, investments, exits and more. Evaluate their financials based on Forbius's post-money valuation and revenue. Forbius Stock Price, Funding, …See details»
Bristol Myers Squibb Enters Agreement to Acquire Forbius, Adding …
Aug 24, 2020 Forbius’s Lead TGF-beta Asset, AVID200, is an Isoform-Selective TGF-beta Inhibitor, Currently in Phase 1 for Oncology and Fibrosis. NEW YORK, NY, USA & …See details»
Forbius doses first patient with AVID100 in Phase 2a triple …
Apr 24, 2019 Forbius, a clinical-stage company that develops novel biologics for the treatment of cancer and fibrosis, has revealed that it has dosed its first patient in a Phase 2a triple negative …See details»
Forbius Agrees to Sell to Bristol Myers Squibb - Cooley
New York – August 25, 2020 – Cooley advised Forbius – a clinical-stage protein engineering company that designs and develops biotherapeutics for the treatment of cancer and fibrotic …See details»
Forbius’ AVID100, a Novel Anti-EGFR ADC, Reports Positive Phase …
Mar 29, 2019 Forbius, a clinical-stage company that develops novel biologics for the treatment of fibrosis and cancer, announces today that it will report the results from its Phase 1 dose …See details»
Forbius (Formation Biologics) Awarded $18.8 Million Grant by
Aug 24, 2018 AUSTIN, Texas--(BUSINESS WIRE)-- Forbius (Formation Biologics) announced today that it has been awarded a Product Development grant totaling $18.75 million from the …See details»
Forbius Announces First Patient Dosed in Phase 2a Triple Negative ...
On April 22, 2019 Forbius, a clinical-stage company that develops novel biologics for the treatment of cancer and fibrosis, reported that the first patient has been dosed in a Phase 2a …See details»
A Phase 1a/2a trial of AVID100, an anti-EGFR antibody-drug …
Methods: Patients with advanced or metastatic epithelial malignancies without available therapy and likely to express EGFR are being enrolled into sequential dose escalation cohorts (Phase …See details»
EGFR抗体药AVID100治疗三阴性乳腺癌（TNBC）进入II期临床
Jan 21, 2022 Forbius是一家临床阶段的生物制药公司，专注于设计和开发用于治疗纤维化和癌症的新型生物制剂，其当前重点是开发靶向表皮生长因子受体（EGFR）和转化生长因 …See details»